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Figure 5. OVA specific serum IgG antibody titers (a) and target cell killing in spleens (b). 
Data shown are from individual mice from a representative experiment of 3 independent 
experiments (n = 5 mice/experiment). ** p < 0.01, *** p < 0.001, **** p < 0.0001
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Figure 1: q vs intensity patterns obtained from SAXS measurements of a) dispersions in water of 
cubosomes with no Quil-A or OVA (blank), only Quil-A, only OVA, and OVA and Quil-A. b) Spray 
dried powders of monoolein and dextran with no Quil-A or OVA (blank), only Quil-A, and with 
OVA and Quil-A.
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Aim
The aim of this study was to spray dry cubosomes with ovalbumin (OVA) as model antigen and 
Quil-A as adjuvant and investigate in vitro characteristics and in vivo immunogenicity following
subcutaneous (s.c.) and oral administration to mice. Since oral vaccination with cubosomes had 
no effect, we applied microcontainers (MC) as oral delivery system, characterized the system in 
vitro and evaluated its oral immunogenicity in vivo as oral booster following s.c. injected primer 
and in an oral prime-boost setting.
Figure 4. In vivo expansion of transgenic CD8+ cells (a and b) and CD4+ cells (c 
and d) in spleens (a and c) and lymph nodes (b and d) following s.c. or oral 
administration. Data in a and c are results from individual mice plus the mean and 
SD from a representative experiment of three independent experiments (n = 5 
mice/experiment). Data in b and d are pooled data from 4-5 mice in each of three 
independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, **** p < 0.0001
1 9 0 2 0 0 2 1 0 2 2 0 2 3 0 2 4 0 2 5 0 2 6 0
- 1 0
- 5
0
5
1 0
1 5
W a v e l e n g t h  ( n m )
E
ll
ip
ti
c
it
y
 (
m
il
li
d
e
g
re
e
s
)
c o n t r o l  f o r  c h a n g e d
s e c o n d a r y  s t r u c t u r e
c u b o s o m e s  w i t h  O V A  a n d  Q u i l - A
n a t i v e  O V A
0 1 0 2 0 3 0 4 0 5 0
0
2 5
5 0
7 5
1 0 0
T i m e  ( h )
F
IT
C
-O
V
A
 r
e
le
a
s
e
d
 (
%
)
0 2 4 6 8
0
2 5
5 0
7 5
1 0 0
T i m e  ( h )
F
IT
C
-O
V
A
 r
e
le
a
s
e
d
 (
%
)
s . c
.  c
u b
o ,
 O
V A
+ Q
u i
l - A
o r
a l  
c u
b o
,  O
V A
+ Q
u i
l - A
 ( l
i q
u i
d )
o r
a l  
c a
p s
u l
e +
M C
+ c
u b
o ,
 O
V A
+ Q
u i
l - A
o r
a l  
c a
p s
u l
e +
M C
+ c
u b
o ,
 Q
u i
l - A
o r
a l  
c a
p s
u l
e ,  
M C
,  O
V A
+ Q
u i
l  A
o r
a l  
c a
p s
u l
e ,  
O V
A +
Q u
i l -
A
1 0
1 0 0
1 0 0 0
1 0 0 0 0
1 0 0 0 0 0
O
V
A
 s
p
e
c
if
ic
 I
g
G
 t
it
e
r
*
* * *
* * *
* *
* *
s . c
.  c
u b
o ,
 O
V A
+ Q
u i
l - A
o r
a l  
c u
b o
,  O
V A
+ Q
u i
l - A
 ( l
i q
u i
d )
o r
a l  
c a
p s
u l
e +
M C
+ c
u b
o ,
 O
V A
+ Q
u i
l - A
o r
a l  
c a
p s
u l
e +
M C
+ c
u b
o ,
 Q
u i
l - A
o r
a l  
c a
p s
u l
e ,  
M C
,  O
V A
+ Q
u i
l  A
o r
a l  
c a
p s
u l
e ,  
O V
A +
Q u
i l -
A
- 1 0 0
- 5 0
0
5 0
1 0 0
1 5 0
%
 K
il
li
n
g
* * *
0 . 0 5 0 . 1 0 0 . 1 5 0 . 2 0 0 . 2 5 0 . 3 0
q ( Å - 1 )
In
te
n
s
it
y
 (
a
.u
.)
l i d ,  1 3 8  m in
l id ,  6 0  m in
l id ,  3 0  m in
n o  l i d ,  3 0  m in
0 . 0 5 0 . 1 0 0 . 1 5 0 . 2 0 0 . 2 5 0 . 3 0
q ( Å - 1 )
In
te
n
s
it
y
 (
a
.u
.)
l i d ,  2 1  m in
l id ,  0  m in
a ) b )
s . c
.  c
u b
o ,
 O
V A
+ Q
u i
l - A
o r
a l  
c a
p s
u l
e +
c u
b o
,  O
V A
+ Q
u i
l - A
o r
a l  
c a
p s
u l
e +
M C
+ c
u b
o ,
 O
V A
+ Q
u i
l - A
o r
a l  
O V
A +
Q u
i l  A
 i n
 P
B S
o r
a l  
c a
p s
u l
e +
M C
+ c
u b
o ,
 Q
u i
l - A
0 . 1
1
1 0
1 0 0
1 0 0 0
1 0 0 0 0
1 0 0 0 0 0
1 0 0 0 0 0 0
O
V
A
 s
p
e
c
if
ic
 I
g
G
 t
it
e
r
***
a) b)
Figure 3. Release of FITC-OVA from cubosomes (also 
containing Quil-A) in 9.5 mM PBS at pH 7.3 and 37oC. The 
insert shows the release over the first 8 h. Data are expressed 
mean ± SD (n = 4).
Figure 2. Representative circular dichroism 
spectra of spray dried cubosomes with OVA 
and Quil-A after secondary drying at 86oC for 
24 h (concentration of OVA was 106 µg/mL). 
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Figure 7. pH in the GI tract of mice at 37o. 
Whiskers on the boxplots indicate maximum 
and minimum (n = 5). Averages are written 
above each group.
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Figure 6. Microcontainers found in 
segments of the GI tract when sacrificing 
mice 60 or 90 min after oral gavage. Data 
are presented as mean±SD (n = 3).
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Figure 9. OVA specific serum IgG antibody 
titers from individual mice from a 
representative experiment of 3 independent 
experiments (n = 5 mice/experiment). 
*** p < 0.001
Figure 8. q vs. intensity patterns obtained from 
SAXS measurements of cubosomes with OVA and 
Quil-A released at 37oC from microcontainers with or 
without Eudragit L100-55 lids as indicated in PBS (a) 
and mouse intestinal medium (b). 
Figure 10. OVA specific serum IgG antibody titers (a) and target cell killing in spleens (b). Data shown 
are from individual mice from a representative experiment of 2 independent experiments (n = 5 
mice/experiment). * p < 0.05, ** p < 0.01, *** p < 0.001
Cubosomes with OVA and Quil-A stimulate 
strong humoral and cellular immune responses 
after s.c. administration but not oral. MC 
protect cubosomes in vitro and release them in 
the small intestine. MCs improve immunogen-
icity in vivo of oral boosters but no effect is 
seen after oral primer and booster.
